Gentex Reports Fourth Quarter and Year End 2023 Financial Results
ZEELAND, Mich., Jan. 26, 2024 (GLOBE NEWSWIRE) — Gentex Corporation (NASDAQ: GNTX), a leading supplier of digital vision, connected car, […]
PEL 83 Exploration Campaign Update – Second Significant Light Oil Discovery at Mopane-1X
TORONTO, Jan. 26, 2024 (GLOBE NEWSWIRE) — Sintana Energy Inc. (TSX-V: SEI, OTCQB: SEUSF) (“Sintana” or the “Company”) is pleased […]
Trailbreaker Resources Grants Stock Options
VANCOUVER, British Columbia, Jan. 26, 2024 (GLOBE NEWSWIRE) — Trailbreaker Resources Ltd. (TBK.V) (“Trailbreaker” or “the Company”) announces that subject […]
ParaZero Has Enabled Precedent-Setting Light UAS Operator Certificate Approval in Denmark
The light UAS operator certificate (LUC) approval allows for self-authorized cross-border drone operations throughout the European Union without additional approval […]
AppTech Payments Announces Strategic Partnership with First Inning Ventures to Expand Commerse™ Suite in the International and Domestic Sports Market
CARLSBAD, Calif., Jan. 26, 2024 (GLOBE NEWSWIRE) — AppTech Payments Corp. (Nasdaq: APCX) (“AppTech” or the “Company”), a pioneering Fintech company […]
BullFrog AI Strengthens Scientific Advisory Board with the Addition of Dr. Gwenn Smith and Dr. Jeremiah Wala
GAITHERSBURG, Md., Jan. 26, 2024 (GLOBE NEWSWIRE) — BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) (“BullFrog AI” or the “Company”), […]
CRB-701 (SYS6002) A Next Generation Nectin-4 Targeting Antibody Drug Conjugate Demonstrates Encouraging Safety and Efficacy in Patients with Nectin-4 Positive Tumors in First-In-Human Study Presented at ASCO-GU 2024
Q3W schedule of CRB-701 (SYS6002) demonstrates a 43% ORR and 71% DCR at predicted therapeutically relevant doses All assessable nectin-4 […]
DraftKings to Release Fourth Quarter and Full Year 2023 Results on February 15, 2024 and Host Conference Call on February 16, 2024
BOSTON, Jan. 26, 2024 (GLOBE NEWSWIRE) — DraftKings Inc. (Nasdaq: DKNG) (the “Company” or “DraftKings”) today announced that it will […]
Apellis Announces Negative CHMP Opinion for Pegcetacoplan for GA in the European Union and Plans to Seek Re-Examination of Application
WALTHAM, Mass., Jan. 26, 2024 (GLOBE NEWSWIRE) — Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) announced today that the Committee for Medicinal […]
South Plains Financial, Inc. Reports Fourth Quarter and Year-End 2023 Financial Results
LUBBOCK, Texas, Jan. 26, 2024 (GLOBE NEWSWIRE) — South Plains Financial, Inc. (NASDAQ:SPFI) (“South Plains” or the “Company”), the parent […]
